Latest Conference Coverage

Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.

Steve Chung, MD: Perampanel's Effect on Insomnia in Patients With Epilepsy

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.

Bhooma Aravamuthan, MD, DPhil: Taking a Multi-Specialist Approach to Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.

Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.

Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.

Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.

Ponesimod Displays Superiority in Relapsing MS Treatment

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

Galcanezumab Has Significant Impact for Patients With Refractory Migraine

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

Lasmiditan Improves Migraine-Related Disability

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.

Bhooma Aravamuthan, MD, DPhil: Inconsistencies in Diagnosing Cerebral Palsy

The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.

Ubrogepant More Effective in Mild Pain Migraine Attacks

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.

Erenumab Shows Long-Term Success in Migraine Treatment

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.

Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.

Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Rimegepant Shows Early Efficacy in Acute Migraine Treatment

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.